Rheumatoid arthritis: Clinical guideline 2003

South African Medical Journal

Volumn 93, Issue 12 II, 2003, Pages 991-1011

  Kalla, A A ^a   Stanwix, A ^a   Gotlieb, D ^a   Asherson, R A ^a   Mody, G M ^a  

^a South African Medical Association   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ANTIRHEUMATIC AGENT; AURANOFIN; AUROTHIOMALATE; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CELECOXIB; CHLOROQUINE; CYCLOSPORIN; ERGOCALCIFEROL; ETANERCEPT; FOLIC ACID; GLUCOCORTICOID; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENICILLAMINE; PREDNISONE; PROTON PUMP INHIBITOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROFECOXIB; SALAZOSULFAPYRIDINE; TRAMADOL; UNINDEXED DRUG; WARFARIN;

ABDOMINAL PAIN; ALOPECIA; ANALGESIC ACTIVITY; ANEMIA; ANOREXIA; APLASTIC ANEMIA; ARTICLE; ASEPTIC MENINGITIS; ASTHMA; AUTOIMMUNE HEMOLYTIC ANEMIA; BONE MARROW HYPOPLASIA; BONE MARROW SUPPRESSION; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DIAGNOSTIC TEST; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ACTIVITY; DRUG BIOAVAILABILITY; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; EPIDEMIOLOGICAL DATA; FEMALE; FEMALE FERTILITY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HYPERTENSION; INJECTION SITE REACTION; INTERSTITIAL NEPHRITIS; KIDNEY DYSFUNCTION; LACTATION; LIVER TOXICITY; LUNG TOXICITY; LYMPHOPROLIFERATIVE DISEASE; MEDICAL ASSESSMENT; MENOPAUSE; MOOD DISORDER; MOUTH ULCER; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROMUSCULAR DISEASE; OCCUPATIONAL THERAPY; OLIGOSPERMIA; OSTEOPOROSIS; OUTCOMES RESEARCH; PANCYTOPENIA; PATHOPHYSIOLOGY; PATIENT EDUCATION; PEPTIC ULCER; PHARYNGITIS; PHOTOSENSITIVITY; PHYSIOTHERAPY; PNEUMONIA; PRACTICE GUIDELINE; PREGNANCY; PSYCHOSIS; REMISSION; RENOVASCULAR HYPERTENSION; RETINA MACULOPATHY; RHEUMATOID ARTHRITIS; RHINITIS; SIDE EFFECT; SKIN PIGMENTATION; STEVENS JOHNSON SYNDROME; STOMACH DISEASE; STOMACH EROSION; STOMATITIS; TINNITUS; TREATMENT PLANNING; TREMOR; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; VERTIGO;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES; SEVERITY OF ILLNESS INDEX;

EID: 0346494526     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (103)

1. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines: Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996; 39: 713-722.
2. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines: Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996; 39: 723-731.
3. Kremer JM, Alarcon GS, Lightfoot RW jun, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37: 316-328.
4. Mae Gregor AJ, Riste LK, Hazes JM, Silman AJ. Low prevalence of rheumatoid arthritis in black Caribbeans compared with whites in inner city Manchester. Ann Rheum Dis 1994; 53: 293-297.
5. Solomon L, Robin G, Valkenburg HA. Rheumatoid arthritis in an urban South African Negro population. Ann Rheum Dis 1975; 34: 128-135.
6. Beighton P, Solomon L, Valkenburg RA. Rheumatoid arthritis in a rural South African Negro population. Ann Rheum Dis 1975; 34: 136-141.
7. Meyers OL, Daynes G, Beighton P. Rheumatoid arthritis in a tribal Xhosa population in the Transkei, Southern Africa. Ann Rheum Dis 1997; 36: 62-65.
8. Meyers OL. The prevalence of rheumatic disease in a rural Coloured population in Namaqualand. MD Thesis, University of Cape Town, 1982.
9. Mody GM. Rheumatoid arthritis in the Western Cape - a clinical study. MD thesis, University of Cape Town, 1982.
10. Wolfe F, Kleinheksel SM, Khan MA. Prevalence of familial occurrence in patients with rheumatoid arthritis. Br J Rheumatol 1988; 27: suppl 2, 150-152.
11. Me Cusker CT, Singal DR Molecular relationships between the class II antigens susceptibility in rheumatoid arthritis (Editorial). J Rheumatol 1988; 15: 1050-1053.
12. Schiff B, Mizrachi Y, Orgad S, Yaron M, Gazit E. Association of HLA-Aw31 and HLA-DR1 with adult rheumatoid arthritis. Ann Rheum Dis 1982; 41: 403-404.
13. Woodrow JC, Nichol FE, Zaphiropoulos G. DR antigens and rheumatoid arthritis: a study of two populations. BMJ Clin Res 1981; 293: 1287-1288.
14. Mody GM, Hammond MG, Naidoo PD. HLA association with rheumatoid arthritis in African blacks. J Rheumatol 1999; 16: 1326-1328.
15. Martell RW, Do Toit ED, Kalla AA, Meyers OL. Association of rheumatoid arthritis with HLA in three South African populations - whites, blacks and a population of mixed ancestry. S Afr Med J 1989; 76: 189-190.
16. Pile KD, Tikly M, Bell JI, Wordsworth BP. HLA-DR antigens and rheumatoid arthritis in Blacks: a study of ethnic groups. Tissue Antigens 1992; 39: 138-140.
17. Decker JL, Malone DG, Haraoui B, et al. NIH conference. Rheumatoid arthritis: evolving concepts of pathogenesis and treatment. Ann Intern Med 1984; 101: 810-824.
18. Sharp JT, Wolfe F. Mitchell DM, Bloch DA. The progression of erosion and joint space narrownig scores in rheumatoid arthritis during the first twenty-five years of treatment. Arthritis Rheum 1991; 34: 660-668.
19. Arnett FC, Edworthy SM, Block DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324.
20. Patel YI. Rheumatoid factor - does the patient have arthritis? S Afr Med J 1999; 89: 742-743.
21. Maddison PJ. Autoantibody profile. In: Madison PJ, Isenberg DA, Woo P. Glass DN, eds. Oxford Textbook of Rheumatology 2nd ed. Oxford: Oxford University Press, 1998: 665-676.
22. Scott DL. Prognostic factors in early rheumatoid arthritis. Rheumatology 2000; 39: suppl 1: 24-29.
23. Alarcon GS, Acton RT, Koopman WJ, Barger BO. CREG antigens differentially influence expression of extraarticular manifestations in whites and blacks with rheumatoid arthritis. Semin Arthritis Rheum 1983; 13: 169-173.
24. Pincus T, Callahan LF. What is the natural history of rheumatoid arthritis? Rheum Dis Clin North Am 1993; 19: 123-151.
25. Pincus T. Assessment of long-term outcomes of rheumatoid arthritis. How choices of measures and study designs may lead to apparently different conclusions. Rheum Dis Clin North Am 1995; 21: 619-654.
26. McQueen FM. Magnetic resonance imaging in early inflammatory arthritis: what is its role? Rheumatology 2000; 39: 700-706.
27. Scott DL. Prognostic factors in early rheumatoid arthritis. Rheumatology 2000; 39: suppl 1, 24-29.
28. Emery P, Marzo H, Proudman S. Management of patients with newly diagnosed rheumatoid arthritis. Rheumatology 1999; 38: suppl, 27-31.
29. Wood PHN. Appreciating the consequences of disease: the international classification of impairments, disabilities and handicaps. WHO Chron 1980; 34: 376-380.
30. Fries JF. The dimensions of health outcomes: the Health Assessment Questionnaire. J Rheumatol 1982; 74: 786-793.
31. Fries JF. Toward an understanding of patient outcome measurement. Arthritis Rheum 1983(a); 26: 697-704.
32. Fries JF. Assessment of disability: from first to future principles. Br J Rheumatol 1983(b); 22: 48-58.
33. Kirwan JR. A theoretical framework for process, outcome and prognosis in rheumatoid arthritis. J Rheumatol 1991; 19: 333-336.
34. Kosinski M, Keller SD, Hatoum HT, Kong SX, Ware JE. The SF-36 Health Survey as a generic outcome measure in clinical trials of patients with osteoarthritis and rheumatoid arthritis: tests of data quality, scaling assumptions and score reliability. Med Care 1999; 37: 5 suppl, MS10-22.
35. The American College of Rheumatology revised criteria for classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992; 35: 498-502.
36. Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24: 1308-1315.
37. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-735.
38. Callahan LF. The burden of RA: Facts and figures. J Rheumatol 1998; 25: suppl 53, 8-12.
39. Pincus T, Callahan LF, Sale WG. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1994; 27: 864-872.
40. Scott DL, Symmons DP, Coulton BL, Popert AJ. Long term outcome of treating rheumatoid arthritis after 20 years. Lancet 1987; 1: 1108-1111.
41. Michell DM, Spitz PW, Young DY, Block DA, McShane DJ, Fries JF. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986; 29: 706-714.
42. Pincus T, Callahan LF. Remodeling the pyramid or remodeling the paradigms concerning rheumatoid arthritis - lessons from Hodgkin a disease and coronary heart disease. J Rheumatol 1990; 17: 1582-1585.
43. Leigh JP, Fries JF. Mortality predictors among 263 patients with rheumatoid arthritis. J Rheumatol 1991; 18: 1307-1312.
44. Fries JF; Williams CA, Morfeld D, Singh G, Sibley J. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 1996; 39: 616-622.
45. Wilske KR, Healy LA. Remodeling the pyramid - a concept whose time has come. J Rheumatol 1989; 16: 565-567.
46. O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate, sulphasalazine and hyrochloniquine or a combination of these medications. N Engl J Med 1996; 334: 1287-1291.
47. Doherty M, Hazleman BL, Hutton CW, Maddison PJ, Perry JD. Rheumatology Examination and Injection Techniques. 2nd ed. London: WB Saunders, 1999.
48. Larsen A. The relation of radiographic changes to serum acute-phase proteins and rheumatoid factor in 200 patients with rheumatoid arthritis. Scand J Rheumatol 1988; 17: 123-129.
49. Wilder-Smith CH, Hill L, Spargo K, Kalla A. Treatment of severe pain from osteoarthritis with slow-release tramadol or dihydrocodeine in combination with NSAIDs: a randomised study comparing analgesia, antinociception and gastrointestinal effects, Pain 2001; 91: 23-31.
50. Berlin P. Current use of analgesics for rheumatological pain. European Journal of Pain 2000; 4: suppl A, 9-13.
51. Gabriel S, Jaakkimeinen L, Bombardier C. Risk factors for serious gastrointestinal complications related to use of non-steroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115: 787-796.
52. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241-249.
53. Vane JR. Inhibition of prostaglandin synthesis as mechanism of action for aspirin-like drugs. Nature (New Biology) 1971; 231: 232-235.
54. Schnitzer TJ, Truitt K, Fleischmann R, et al. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Clin Ther 1999; 21: 1688-1702.
55. Emery P, Zeidler H, Kvien TK, et al. Colecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized double-blind comparison. Lancet 1999; 354: 2106-2111.
56. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs non-steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial. JAMA 2000; 284: 1247-1255.
57. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastro-intestinal toxicity of rofecoxib and caproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-1528.
58. Fries JF, Bloch DA, Sharp JT, McShane DJ. Assessment of radiologic progression in rheumatoid arthritis. Arthritis Rheum 1986; 29: 1-9.
59. Wolfe F. 50 years of antirheumatic therapy: the prognosis of RA. J Rheumatol 1990; 17: 24-32.
60. Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiological damage in rheumatoid arthritis within the first two years. J Rheumatol 1989; 16: 585-591.
61. Cash JM, Klippel JH. Second line drug therapy for rheumatoid arthritis. N Engl J Med 1991; 330; 1368-1375.
62. Weinblatt ME, Weissman BN, Holdsworth DE, et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis - 84 month update. Arthritis Rheum 1992; 35: 129-137.
63. Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis - update after a mean of 90 months. Arthritis Rheum 1992; 35: 138-145.
64. Situnayake RD, Grindulis KA, McConkey B. Longterm treatment of rheumatoid arthritis with sulphasalazine, gold or penicillamine: a comparison using life table methods. Ann Rheum Dis 1987; 46: 177-183.
65. Ferraz MB, Pinheiro GR, Helfenstein M, et al. Combination therapy with methotrexate and chloroquine in rheumatoid arthritis. A multicenter randomized placebo-controlled trial. Scand J Rheumatol 1994; 23: 231-236.
66. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with a placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999; 353: 259-266.
67. Sharp JT, Strand V, Leung H, et al. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 2000; 43; 495-505.
68. Tugwell P, Wells G, Strand V, et al. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Arthritis Rheum 2000; 43: 506-514.
69. Elliott MJ, Maini RN, Feldman M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor μ (CA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-1110.
70. Maini RN, Breedeveld FC, Kaldon JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor μ monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 4: 1552-1563.
71. Moreland LW, Baumgartner SW, Tindall EA, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75) - Fc fusion protein. N Engl J Med 1997; 337: 141-147.
72. Furst DE, Breedevold FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis 2002; 61: suppl II, ii2 - ii8.
73. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-259.
74. Criscione LG, William St Clair E. Tumour necrosis factor-a antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol 2002; 14: 204-211.
75. O'Dell JR, Paulsen G, Haire CE, et al. Treatment of early seropositive rheumatoid arthritis with minocycline: four-year follow-up of a double blind, placebo-controlled trial. Arthritis Rheum 1999; 42: 1691-1705.
76. Bluhm GB, Sharp JT, Tilley BC, et al, Radiographic results from the Minocycline in Rheumatoid Arthritis (MIRA) Trial. J Rheumatol 1997; 24: 1295-1302.
77. Boers M. The case for corticosteroids in the treatment of early rheumatoid arthritis (Editorial). Rheumatology 1999; 38: 95-97.
78. Morrison E, Capell HA. Corticosteroids in rheumatoid arthritis-the case against (Editorial). Rheumatology 1999; 38: 97-100.
79. Laam RSJM, Jansen Th A, Van Riel TLCM. Glucocorticoid steroids in the management of rheumatoid arthritis. Rheumatology 1999; 38: 6-12.
80. American College of Rheumatology Task Force on Osteoporosis Guidelines: Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996; 39: 1791-1801.
81. Smolen JS, Breedeveld FC, Burmester DR, et al. Consensus statement on the initiation and entinuation of tumour necrosis factor blocking therapies in rheumatoid arthritis. Ann Rheum Dis 2000; 59: 504-505.
82. Bresnihan B, Alvaro-Garcia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196-2204.
83. Jiang Y, Genant HK, Watt J, et al. A multicenter, double-blind, dose-ranging, randomised, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000; 43: 1001-1009.
84. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate. Arthritis Rheum 2002; 46: 574-578.
85. Stein CM, Pincus T, Yocum D, et al. Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks: an open-label extension study. The Methotrexate-Cyclosporine Combination Study Group. Arthritis Rheum 1997; 40: 1843-1851.
86. Lukert BP, Raise LG. Glucocorticoid-induced osteoporosis: Pathogenesis and management. Ann Intern Med 1990; 112: 352-364.
87. Spector TD, Hall GM, McCloskey EV, Kanis JA. Risk of vertebral fractures in women with rheumatoid arthritis. BMJ 1993; 306: 558-563.
88. Reid IR, Heap SW. Determinants of vertebral mineral density in patients receiving chronic glucocorticoid therapy. Arch Intern Med 1990; 150: 2545-2548.
89. Hall GM, Dansel M, Doyle DV, Spector TD. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 1994; 37: 1499-1505.
90. Adachi JD, Benson WG, Bianchi F, et al. Vitamin D and calcium in the prevention of corticosteroid-induced osteoporosis: a 3 year follow up. J Rheumatol 1996; 23: 995-1000.
91. Saag KG, Emkey R, Schnitzer TJ, et al. for the glucocorticoid-induced osteoporosis intervention study group. Alendronate for the prevention and treatment of glueocorticoid-induced osteoporosis. N Engl J Med 1998; 339: 292-299.
92. Hough S. Diagnosis and management of osteoporosis. S Afr Med J 2000; 90; 907-944 (part 2).
93. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949; 140: 659-662.
94. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995; 533: 137-141.
95. O'Dell JR, Leff R, Paulsen G, Haire C et al. Treatment of rheumatoid arthritis with methotrexate and hydrochloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomised, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1164-1170.
96. Van Riel PLCM, Wijnands MJH, Van der Putte LBA. Evaluation and management of active inflammatory disease. In: Klippel JH, Dieppe PA. eds. Rheumatology. 2nd ed. St Louis: Mosby, 1997; 14.1-12.
97. Bakker AC, Joosten LAB, Arntz OJ, et al. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum 1997; 40: 893-900.
98. Tyndall A, Gratwohl A. Haemopoietic stem and progenitor cells in treatment of severe auto-immune diseases. Ann Rheum Dis 1996; 55: 149-151.
99. Sieper J, Kary S, Sorensen H, et al. Oral collagen II treatment in early rheumatoid arthritis: a double blind placebo-controlled randomized trial. Arthritis Rheum 1995; 39: 41-51.
100. Contraceptive protective RA Brennan P, Bankhead C, Silman A, Symmons D. Oral contraceptives and rheumatoid arthritis: results from a primary care-based incident case-control study. Semin Arthritis Rheum 1997; 26: 817-823.
101. Janssen NM, Genta MS. The effects of immunosuppressive and acti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med 2000; 160: 610-619.
102. Sambrook PN. The skeleton in rheumatoid arthritis: common mechanisms for bone erosion and osteoporosis? J Rheumatol 2000; 27: 2541-2542.
103. Sinigaglia L, Nervetti A, Mela Q, et al. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. J Rheumatol 2000; 27: 2582-2589.